BioFinance 2012 to Showcase Promising Investment Opportunities in the Life Sciences
TORONTO, May 23, 2012 /CNW/ - BioFinance 2012, Canada's leading investor conference for the life sciences, will feature presentations from more than 45 public and private life science companies, and 13 investor panels comprised of industry experts and thought leaders. The event will be held on May 29 and 30, 2012, at the St. Andrew's Club & Conference Centre in Toronto, Canada.
"This year has already seen encouraging news for the sector including a huge resurgence in Canadian venture capital. There have also been many Canadian success stories during 2011, most significantly, the acquisition of Enobia Pharma by Alexion Pharmaceuticals, Inc. for $610 million, the largest transaction in recent Canadian history," said Mr. Michael Stinson, Executive Director of BioFinance Canada. "With an increased amount of venture capital now available to fund Canadian biotech companies, as well as the continued interest from U.S. venture capital, 2012 could be a very promising year for many life science companies."
Panels at this year's conference will feature:
- Canadian venture capital fund managers discussing the newly established funds available for the life sciences sector
- U.S. institutional and venture capital fund managers providing their perspective on the competition for small cap funding in Canada
- Investment bankers from the U.S. analyzing the current state of the US capital markets and opportunities for Canadian companies
- Top U.S. and Canadian healthcare analysts looking ahead to the most important milestones for the sector in 2012
- Participants in the acquisition of Enobia Pharma by Alexion Pharmaceuticals, Inc. highlighting the details of the $610 million transaction
"Many public Canadian healthcare companies celebrated clinical and regulatory successes in 2011 or moved their products closer to critical data and regulatory decisions," said Dr. Wayne Schnarr, Healthcare Consultant for TMX Equicom. "Other companies continued to deliver sales, profits, dividends and distributions for their shareholders."
About BioFinance Canada
BioFinance is the leading investor conference in Canada for the life sciences industry. The two day event brings together key industry players and companies interested in investment opportunities and issues affecting the life sciences sector. Presenting companies span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, ag-biotech, and research services. For more information or to register for BioFinance 2012, please visit www.biofinance.ca.
For further information:
Michael Stinson
Executive Director
BioFinance Canada
1-866-342-4933
[email protected]
Share this article